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The high affinity receptor for human granulocyte-
macrophage colony-stimulating factor (GM-CSF) con-
sists of a cytokine-specific a-subunit (hGMRa) and a
common signal-transducing b-subunit (hbc) that is
shared with the interleukin-3 and -5 receptors. We have
previously identified a constitutively active extracellu-
lar point mutant of hbc, I374N, that can confer factor
independence on murine FDC-P1 cells but not BAF-B03
or CTLL-2 cells (Jenkins, B. J., D’Andrea, R. J., and
Gonda, T. J. (1995) EMBO J. 14, 4276–4287). This re-
stricted activity suggested the involvement of cell type-
specific signaling molecules in the activation of this mu-
tant. We report here that one such molecule is the mouse
GMRa (mGMRa) subunit, since introduction of mGMRa,
but not hGMRa, into BAF-B03 or CTLL-2 cells express-
ing the I374N mutant conferred factor independence.
Experiments utilizing mouse/human chimeric GMRa
subunits indicated that the species specificity lies in the
extracellular domain of GMRa. Importantly, the re-
quirement for mGMRa correlated with the ability of
I374N (but not wild-type hbc) to constitutively associate
with mGMRa. Expression of I374N in human factor-de-
pendent UT7 cells also led to factor-independent prolif-
eration, with concomitant up-regulation of hGMRa sur-
face expression. Taken together, these findings suggest
a critical role for association with GMRa in the consti-
tutive activity of I374N.
GM-CSF1 is a potent cytokine that promotes the survival,
proliferation, differentiation, and functional activity of a wide
variety of hemopoietic cell types including monocytes/macro-
phages, granulocytes, and myeloid progenitor cells (reviewed in
Ref. 1). Like other cytokines, GM-CSF exerts its biological
activities through binding to specific receptors on the surface of
target cells. The high affinity receptor for human GM-CSF
(hGMR) is composed of a cytokine-specific a-subunit (hGMRa)
associated with a common signal-transducing b-subunit (hbc)
that is also utilized by the IL-3 and IL-5 receptors (2–6), all of
which belong to the cytokine receptor family (reviewed in Ref.
7). Members of this family are characterized by a structurally
conserved extracellular cytokine receptor module (CRM) of
about 200 amino acids that consists of two fibronectin type
III-like domains (8). The b-subunit has two CRMs, whereas the
a-subunits contain one CRM and an additional N-terminal
domain of about 100 amino acids.
Although the stoichiometry of subunits in active hGMR,
hIL-3R, and hIL-5R complexes remains unresolved, it has be-
come clear that ligand-induced a-b-subunit heterodimerization
is a key step in the formation of these complexes (9, 10). More
recently, it has been shown that b-subunit homodimers are
found in active hGMR (11) and human IL-3R (12) complexes
and that the functional hGMR complex may contain at least
two a-subunits (13). Taken together, these results suggest that
the a- and b-subunits may form higher order receptor com-
plexes, and indeed it has been proposed that the GMR/IL-3R/
IL-5R normally functions as an a2b2 tetramer (10, 12, 13).
The isolation of constitutively active cytokine receptor mu-
tants has provided a useful tool for examining the normal
activation process of some receptors (e.g. erythropoietin recep-
tor and c-Mpl (14, 15)), since these mutant receptors most
likely mimic the structure of the normal cytokine-activated
receptors. With regard to the GMR/IL-3R/IL-5R system, we
have previously combined random mutagenesis with retroviral
expression cloning to identify constitutively activating point
mutations in hbc by virtue of their ability to confer factor-
independent proliferation on mouse factor-dependent FDC-P1
cells (16, 17). One of these mutations, V449E, is located in the
transmembrane domain of hbc and is similar to an activating
mutation in the neu/c-erbB-2 oncogene (18, 19). By analogy,
this mutant most likely acts by inducing hbc homodimeriza-
tion. Another group of activating point mutations, exemplified
by I374N, lies in the extracellular region of hbc; however, it is
unclear precisely how this group might affect receptor function.
Interestingly, only certain transmembrane mutants, such as
V449E, were able to confer factor independence on mouse factor-
dependent BAF-B03 cells, suggesting that the I374N mutation
activates hbc in a cell type-specific manner.
One possible explanation for the cell type specificity of the
I374N mutant is that a molecule that is present in FDC-P1
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(and other myeloid) cells is required for its constitutive activity.
We report here the use of retroviral expression cloning to
identify the mouse GMRa (mGMRa) subunit as one such mol-
ecule and show that one effect of the I374N mutation is to
induce constitutive association with mGMRa.
EXPERIMENTAL PROCEDURES
Cell Lines—BOSC 23 (20) and C2 (21) ecotropic retroviral packaging
cell lines were maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal calf serum. The BING amphotropic retroviral
packaging cell line was kindly provided by Prof. Suzanne Cory (Walter
and Eliza Hall Institute, Melbourne, Victoria, Australia) with permis-
sion from Dr. Warren Pear (MIT, Cambridge, MA) and was maintained
as described above. The CTL-EN subline of the mouse IL-2-dependent
cell line, CTLL-2 (22), was kindly provided by Dr. John Norton (Pater-
son Institute for Cancer Research, Manchester) and was maintained as
described previously for CTLL-2 cells (16). Mouse IL-3-dependent BAF-
B03 cells (23) were maintained as described previously (16). Human
factor-dependent UT7 cells (24) were maintained in Dulbecco’s modified
Eagle’s medium plus 10% fetal calf serum supplemented with 2 ng/ml
human GM-CSF.
Construction of the FDC-P1 cDNA Library—cDNA library construc-
tion was performed essentially as described by Rayner and Gonda (25).
Briefly, cDNA was synthesized from the mouse IL-3/GM-CSF-depend-
ent myeloid cell line FDC-P1 (26) and size-selected for cDNA fragments
greater than 500 base pairs. Following digestion with BamHI and XhoI,
the size-selected cDNA was ligated directionally into the pRUFNeo
retroviral expression vector (25). The library was amplified in Esche-
richia coli by electroporation of aliquots of the ligated FDC-P1 cDNA.
The resultant colonies from each electroporation were harvested, and
plasmid DNA was prepared from each pool.
Infection of Target Cells with the FDC-P1 cDNA Library—Retroviral
DNA was used to generate a library of retroviruses by a modification of
the method described by Rayner and Gonda (25). Briefly, amphotropic
BING packaging cells were transiently transfected using the procedure
described by Jenkins et al. (27) with 10 mg of retroviral plasmid per
60-mm culture dish (seeded 18 h previously with 2 3 106 cells). At 48 h
post-transfection, virus-containing supernatants were filtered and used
to infect ecotropic C2 packaging cells. Infected C2 cells were harvested
and selected in medium containing G418 (400 mg/ml) to generate the
stable G418-resistant C2 retroviral library. BAF-B03 cells expressing
the I374N hbc mutant were infected with the C2 retroviral library by
co-cultivating 3.75 3 105 BAF/I374N cells with 1.2 3 106 irradiated (30
grays) C2 cells for 48 h in each of eight 25-cm2 culture flasks. The
BAF/I374N cells were then harvested, washed, and selected for factor-
independent growth in 24-well multidishes (204 wells, each seeded with
105 cells) in liquid culture medium without factor.
PCR Recovery and Sequencing of cDNAs from Factor-independent
Cells—PCR was performed on 100 ng of genomic DNA (prepared essen-
tially as described by Hughes et al. (28)) with an XL PCR kit (Perkin-
Elmer) under conditions recommended by the manufacturer. The prim-
ers used for amplification were RCF1 (25), which corresponds to the
vector gag sequence approximately 80 base pairs 59 of the polylinker in
the pRUFNeo vector and RCR2 (59-ATAGCCTCTCCACCCAAGCG-39),
which corresponds to the MC1Neo sequence 364 base pairs 39 of the
polylinker. PCR products were agarose gel-purified, and the 59- and
39-ends were sequenced with PCR primers. Internal primers corre-
sponding to cDNA sequences obtained from initial sequencing with PCR
primers were subsequently used to fully sequence PCR products. Se-
quencing reactions were performed using a Taq DyeDeoxy Terminator
Cycle Sequencing kit (Perkin-Elmer), and sequence data were obtained
by running reactions on an ABI Prism 377 DNA Sequencer.
Receptor Expression Constructs—The pRUFNeo/mGMRa expression
construct was generated by subcloning the full-length mGMRa cDNA
recovered from factor-independent BAF/I374N infectants into the
BamHI and HindIII restriction sites of pRUFNeo. The pRUFNeo/
hGMRa expression construct was generated by inserting the cDNA for
hGMRa into the XhoI site of pRUFNeo.
To introduce the 8-amino acid DYKDDDDK FLAG polypeptide (East-
man Kodak Co.) at the N terminus of mGMRa (FmGMRa), a 59 BamHI/
NaeI fragment encoding the signal sequence and first 8 structural
residues of mGMRa was excised from pRUFNeo/mGMRa and replaced
in frame with a PCR-generated BamHI/NaeI fragment from
pcDNA1Neo/FhIL-3Ra (kindly provided by Richard D’Andrea, Hanson
Center for Cancer Research, Adelaide, South Australia, Australia) en-
coding the hIL-3Ra signal sequence, FLAG octapeptide, and first 6
structural residues of hIL-3Ra. The sense primer corresponded to the
T7 promoter sequence and included a BamHI site, and the antisense
primer corresponded to codons 19–24 (as numbered by Kitamura et al.
(5)) of hIL-3Ra and included a NaeI site. The pRUFPuro/FmGMRa
expression vector was constructed by inserting the BamHI/EcoRI
FmGMRa cDNA from pRUFNeo/FmGMRa into the BamHI and EcoRI
sites of the pRUFPuro retroviral expression vector (16).
The HSV-derived 11-amino acid QPELAPEDPED polypeptide (No-
vagen) was inserted after the signal sequence of the wild-type and
I374N mutant b-subunits (between residues Cys16 and Trp17 as num-
bered by Hayashida et al. (4)) by site-directed mutagenesis using the
pAlter-1 system (Promega) in accordance with the manufacturer’s in-
structions. The modified b-subunit cDNAs were subcloned into the
BamHI and HindIII restriction sites of pRUFNeo.
The following GMRa chimeras were generated by PCR amplification
and ligation of the relevant portions of human and mouse GMRa: (i) the
pRUFNeo/hama1 chimera encoding the extracellular and transmem-
brane domains of hGMRa (346 amino acids) and the cytoplasmic do-
main of mGMRa (38 amino acids); (ii) the pRUFNeo/hama2 chimera
encoding the extracellular N-terminal domain of hGMRa (117 amino
acids) and the extracellular CRM, transmembrane, and cytoplasmic
domains of mGMRa (262 amino acids); (iii) the pRUFNeo/Fmaha1 chi-
mera encoding the extracellular and transmembrane domains of
FmGMRa (335 amino acids) and the cytoplasmic domain of hGMRa (54
amino acids); and (iv) the pRUFNeo/Fmaha2 chimera encoding the
extracellular FLAG-tagged N-terminal domain of FmGMRa (111 amino
acids) and the extracellular CRM, transmembrane, and cytoplasmic
domains of hGMRa (283 amino acids). A full description of the tem-
plates and primers used is available upon request.
Extracellular truncations of mGMRa were generated by PCR on the
pRUFNeo/FmGMRa construct with primers designed to amplify the
entire construct except for the desired extracellular sequence to be
removed while leaving the N-terminal signal sequence and FLAG oc-
tapeptide intact. Each PCR was performed with different sense primers
corresponding to codons 97–102 (for maD1) and codons 195–200 (for
maD2) and the same antisense primer corresponding to codons 9–14 of
mGMRa. The blunt ends of each PCR fragment were then ligated
together in frame.
The cytoplasmic truncation mutant of mGMRa was generated by
PCR on the pRUFNeo/FmGMRa construct with RCF1 as the sense
primer and an antisense primer that contained codons 344–339 of the
mGMRa cytoplasmic domain together with a HindIII restriction site
and termination codon. The PCR products were subcloned into the
BamHI and HindIII restriction sites of pRUFNeo.
All PCRs were performed on 20 ng of plasmid DNA with Pfu DNA
polymerase (Stratagene) under conditions recommended by the manu-
facturer. The structures of all mutated or chimeric cDNAs were verified
by sequencing.
Infection of Hemopoietic Cells—Retroviral infection of mouse BAF-
B03 cells and CTL-EN cells was performed using either stably trans-
fected C2 packaging cells (16) or transiently transfected BOSC 23
packaging cells as described previously (27). Infected BAF-B03 cells
were selected in liquid culture medium containing growth factor and
either G418 (1.5 mg/ml) or puromycin (2 mg/ml). Infected CTL-EN cells
were selected as described previously for CTLL-2 cells (16).
Retroviral infection of human UT7 cells was performed using am-
photropic BING packaging cells based on the method for infecting
mouse hemopoietic cells with BOSC 23-derived retroviruses (27).
Briefly, BING cells were transiently transfected with 10 mg of retroviral
DNA, following which infections were performed by co-cultivating 3 3
105 UT7 cells with the BING cells for 48 h in growth medium supple-
mented with 4 mg/ml polybrene. Cells were harvested and selected in
liquid culture medium containing growth factor and G418 at 1.5 mg/ml.
Analysis of Receptor Subunit Expression by Flow Cytometry—Ex-
pression of receptor subunits on the surface of infected cells was de-
tected by high sensitivity immunofluorescence followed by flow cytom-
etry on an Epics-Profile II analyzer (Coulter). High sensitivity
immunofluorescence was performed by incubating cells with primary
antibody followed by biotinylated anti-mouse IgG (Vector Laboratories)
and streptavidin-phycoerythrin (Caltag Laboratories). Expression of
FLAG epitope-tagged mGMRa subunits was detected by staining with
the anti-FLAG monoclonal antibody M2 (Kodak), and expression of
hGMRa subunits was detected by staining with the anti-hGMRa mono-
clonal antibody 8G6 (29). Expression of wild-type and I374N mutant
b-subunits on the surface of infected BAF-B03 cells was detected by
staining with the anti-hbc monoclonal antibody 1C1 (10), whereas HSV
epitope-tagged wild-type and I374N mutant b-subunits expressed on
the surface of human UT7 cells were detected by staining with an HSV
tag monoclonal antibody (Novagen).
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Cell Proliferation Assays—Infected cells were washed twice, and
triplicate samples of equal cell number (5 3 103) were cultured in a
96-well microtiter plate with or without appropriate growth factor for
72 h. Cell proliferation was measured by the CellTiter 96 nonradioac-
tive cell proliferation assay (Promega).
Immunoprecipitation and Immunoblotting—Cells (2 3 107) were cul-
tured overnight in the absence of growth factor and left unstimulated.
Cells were washed with cold PBS containing 20 mM sodium orthovana-
date and lysed on ice in lysis buffer (50 mM Hepes (pH 7.5), 150 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM sodium orthovanadate, 1
mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 1 mM EGTA, 2 mg/ml
iodoacetamide, 0.2 mg/ml trypsin inhibitor (Boehringer Mannheim),
and CompleteTM protease inhibitor (Boehringer Mannheim)) for 15 min.
Insoluble material was removed by centrifugation, and cell lysates were
incubated with primary antibody for 2 h at 4 °C. Antibodies used for
immunoprecipitation were the anti-hbc antibody 8E4 (30) and the anti-
FLAG antibody M2 (Kodak). Immune complexes were precipitated with
75 ml of protein A-Sepharose (Amersham Pharmacia Biotech) for 1 h at
4 °C, washed three times with lysis buffer, and boiled in 13 reducing
SDS sample buffer. In the case of whole cell protein analyses, samples
were lysed in buffer without 10% glycerol, and insoluble material was
removed and boiled in 13 reducing SDS sample buffer.
Immunoprecipitates were separated by SDS-polyacrylamide gel elec-
trophoresis on 10% gels and electrophoretically transferred to Poly-
ScreenR polyvinylidene difluoride membranes (NEN Life Science Prod-
ucts). Membranes were then incubated with the anti-hbc antibody 1C1
(10), the anti-hGMRa antibody 8D10 (29), or the biotinylated anti-
FLAG antibody BIOM2 (Kodak), as indicated, following which the
membranes were washed and incubated with either an alkaline phos-
phatase-conjugated anti-mouse antibody (Amersham Pharmacia Bio-
tech) or a streptavidin-conjugated alkaline phosphatase antibody (Mo-
lecular Probes, Inc., Eugene, OR), as appropriate. Membranes were
washed and subjected to enhanced chemifluorescence detection (Amer-
sham Pharmacia Biotech) as per the manufacturer’s instructions, fol-
lowing which they were scanned on a FluorImager (Molecular Dynam-
ics, Inc., Sunnyvale, CA). For reprobing, membranes were stripped in
50 mM Tris (pH 7.4), 2% SDS, 100 mM b-mercaptoethanol at 55 °C for 20
min; washed; and subsequently probed with the indicated antibodies.
RESULTS
Isolation of Factor-independent BAF/I374N Cells Infected
with an FDC-P1 cDNA Retroviral Expression Library—We
have previously identified a constitutively activating point mu-
tation, I374N, in the extracellular region of hbc by virtue of its
ability to confer factor-independent growth on FDC-P1 cells
(16). Surprisingly, this mutant was unable to confer factor
independence on mouse IL-3-dependent BAF-B03 cells, leading
us to suggest that the cell type-specific activity of this mutant
may reflect the presence of a b-subunit-associated signaling
molecule in FDC-P1 cells, but not in BAF-B03 cells, that is
required by this mutant for constitutive activation (16). We
therefore reasoned that the introduction of such a molecule
from FDC-P1 cells into BAF-B03 cells expressing the I374N
mutant should lead to its constitutive activity and thus render
these cells factor-independent.
Using procedures described previously (25), an FDC-P1
cDNA library (;8.5 3 105 independent plasmid clones, with an
average insert size of 1.1 kb) was generated in the pRUFNeo
retroviral expression vector. As described under “Experimental
Procedures,” the plasmid DNA was used to generate a stable
C2 retroviral library estimated to contain ;3.5 3 106 inde-
pendent viral producer clones, which should adequately repre-
sent all cDNA species present in the plasmid library.
BAF-B03 cells expressing I374N (BAF/I374N) were infected
by co-cultivation with the virus-producing C2 cells at an infec-
tion frequency of 18% (estimated by colony assays in the pres-
ence of G418). As a control, parallel infections were also per-
formed on uninfected BAF-B03 cells and BAF-B03 cells
expressing wild-type hbc. Cells were then selected for factor-
independent growth in 24-well multidishes. After 1 week in the
absence of factor, 37 of 204 wells seeded with 105 infected
BAF/I374N cells contained viable, proliferating cells, while no
such cells were present in control cultures. Factor independ-
ence was not the result of autocrine growth factor production,
since conditioned medium from the factor-independent cell cul-
tures did not support the growth of uninfected BAF-B03 cells
(data not shown).
PCR Recovery of Mouse GMRa cDNA from Factor-independ-
ent BAF/I374N Infectants—To identify the cDNA sequence
carried by the provirus in the factor-independent BAF/I374N
infectants, long range PCR was performed with retroviral
primers on genomic DNA samples from 17 of the 37 factor-
independent cell populations. This revealed a common frag-
ment of approximately 2.3 kb that was amplified from all 17
genomic DNA samples (data not shown); considering the posi-
tions of the PCR primers relative to the cloning sites in pRUF-
Neo, the size of the cDNA insert was estimated to be 1.9 kb. For
8 of the 17 samples, the 2.3-kb fragment was the only PCR
product generated, suggesting that these factor-independent
cell populations contained only one retroviral insertion and
that its presence was responsible for factor independence. Se-
quence analysis of the 1.9-kb cDNA insert recovered from two
of the factor-independent cell populations revealed that it cor-
FIG. 1. Co-expression of FmGMRa with I374N confers factor
independence on BAF-B03 cells. A, flow cytometric analysis of
FmGMRa and b-subunit expression on G418-selected BAF-B03 cells.
Uninfected BAF-B03 cells (uninf) or cells expressing either wild-type
(wt) or I374N b-subunits were infected with a retrovirus encoding the
FmGMRa subunit and stained with an irrelevant control antibody
(dashed line), the anti-hbc antibody 1C1 (thin solid line), and the
anti-FLAG antibody M2 (thick solid line) by high sensitivity immuno-
fluorescence. Cell number and fluorescence are in arbitrary units; the
latter is plotted on a logarithmic scale. Also shown are analyses of cells
not exposed to the FmGMRa virus. B, proliferation of the BAF-B03 cells
depicted in A in the presence of mIL-3 (300 units/ml) or mGM-CSF (80
units/ml) or in the absence of either factor, as indicated. Proliferation
assays were carried out, as described under “Experimental Procedures,”
with 5 3 103 cells plated in triplicate. Error bars indicate the S.E. of the
mean of each triplicate.
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responded to the full-length cDNA for the mGMRa subunit
(31).
Expression of mGMRa with I374N in BAF-B03 and CTL-EN
Cells Results in Factor Independence—To confirm that
mGMRa would allow the constitutive activation of I374N, we
expressed the recovered mGMRa subunit in BAF/I374N cells
and then tested these cells for factor independence. In order to
monitor cell surface expression of mGMRa, a FLAG epitope-
tagged mGMRa (FmGMRa) was generated in the pRUFNeo
vector (see “Experimental Procedures”). This was introduced
into puromycin-resistant BAF/I374N cells as well as wild-type
hbc-expressing and uninfected BAF-B03 cells. Following selec-
tion for G418 resistance, flow cytometric analysis with a FLAG-
specific monoclonal antibody indicated that the FmGMRa sub-
unit was efficiently expressed on the surface of these cells (Fig.
1A). Upon selection for growth in medium without factor, only
BAF-B03 cells co-expressing FmGMRa and I374N exhibited
factor-independent growth (Fig. 1B). The ability of FmGMRa to
behave as wild-type mGMRa was demonstrated by the prolif-
eration of all FmGMRa-infected BAF-B03 cells in response to
mGM-CSF (Fig. 1B).
The observation that the mouse GMRa subunit was required
for the activity of I374N raised the possibility that another
component(s) of the mouse GMR or IL-3R (i.e. mIL-3Ra mbc or
mbIL-3) present in FDC-P1 and BAF-B03 cells might also be
needed. We therefore introduced I374N and, as a control, wild-
type hbc with FmGMRa into mouse IL-2-dependent CTL-EN
cells, which do not express any receptor components belonging
to the GMR or IL-3R. CTL-EN cells are a derivative of CTLL-2
cells engineered for increased expression of the ecotropic ret-
roviral receptor (41),2 thereby rendering them more susceptible
to retroviral infection. We also included the V449E transmem-
brane hbc mutant in this experiment, since it is inactive when
expressed in CTLL-2 cells, although, unlike the I374N mutant,
it does confer factor independence on BAF-B03 cells (16). The
expression of these subunits was confirmed by flow cytometry
(data not shown), following which these cells were tested for
factor-independent proliferation. As shown in Fig. 2, only
CTL-EN cells expressing both FmGMRa and I374N were fac-
tor-independent, thereby indicating that components of the
mouse IL-3R are not required for the constitutive activity of
I374N. In view of this result, all subsequent experiments were
performed in BAF-B03 cells.
The I374N Mutation Induces Constitutive Association of hbc
with mGMRa in BAF-B03 Cells—To examine whether the re-
quirement for mGMRa by I374N might reflect a physical asso-
ciation between these two subunits, BAF-B03 cells co-express-
ing FmGMRa with I374N or, as a control, wild-type hbc were
subjected to immunoprecipitation with an anti-hbc antibody,
followed by immunoblot analysis with an anti-FLAG antibody.
As shown in Fig. 3A, a protein of 60-kDa, consistent with the
predicted size of mGMRa, was detected only in immunoprecipi-
tates from cell lysates expressing FmGMRa and the I374N
mutant. Importantly, the converse immunoprecipitation (with
anti-FLAG antibody) and immunoblot analysis (with anti-hbc
antibody) confirmed the physical association between mGMRa
and the I374N mutant (data not shown). Reprobing the immu-
noblot with an anti-hbc antibody indicated that both wild-type2 J. Norton, personal communication.
FIG. 4. Ligand-independent association of hGMRa with I374N
and wild-type hbc. A and B, uninfected BAF-B03 cells and cells
expressing the indicated hGMR subunits were incubated in medium
with (1) or without (2) hGM-CSF (10 ng/ml), and lysates were immu-
noprecipitated (IP) with the anti-hbc antibody 8E4. Immunoprecipi-
tated proteins were analyzed by immunoblotting (IB) with the anti-
hGMRa antibody 8D10 (A) or with the anti-hbc antibody 1C1 (B). C,
whole cell lysates from the indicated BAF-B03 cells were subjected to
immunoblotting with the anti-hGMRa antibody 8D10.
FIG. 2. Factor-independent proliferation of CTL-EN cells co-
expressing FmGMRa and the I374N mutant. Proliferation of
CTL-EN cells expressing the indicated subunits in the absence of factor.
Cells were maintained in mouse IL-2 (4 ng/ml) and the appropriate drug
selection prior to assay for factor-independent growth.
FIG. 3. Co-immunoprecipitation of FmGMRa and I374N from
BAF-B03 cells. A and B, uninfected BAF-B03 cells and cells expressing
the indicated subunits were incubated in medium without factor, and
lysates were immunoprecipitated (IP) with the anti-hbc antibody 8E4.
Immunoprecipitated proteins were analyzed by immunoblotting (IB)
with the anti-FLAG antibody M2 (A) or with the anti-hbc antibody 1C1
(B). C, whole cell lysates from the indicated BAF-B03 cells were sub-
jected to immunoblotting with the anti-FLAG antibody M2.
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and I374N b-subunits were immunoprecipitated from the ap-
propriate cell lysates (Fig. 3B). Furthermore, immunoblot anal-
ysis of whole cell lysates with an anti-FLAG antibody indicated
that the total levels of FmGMRa protein present in lysates from
all cell populations were comparable (Fig. 3C). Together, these
observations indicate that the I374N mutation acts, at least in
part, by inducing constitutive association of hbc with mGMRa.
The constitutive association of mGMRa with the I374N mu-
tant was reminiscent of the ability of human GMRa to associ-
ate with wild-type hbc in the absence of GM-CSF (32). We
therefore examined the ability of I374N to associate with
hGMRa in the absence of ligand, since a failure to do so could
explain our previous observation that co-expression of hGMRa
did not allow constitutive activity of I374N in BAF-B03 cells
(Refs. 16 and 27; Fig. 7). The experiment illustrated in Fig. 4A
shows, however, that both mutant and wild-type hbc could
associate equally well with hGMRa in the absence (or presence)
of ligand, as judged by co-immunoprecipitation from BAF-B03
cells expressing both subunits. Equivalent levels of expression
of the b- and a-subunits are confirmed by the analyses of Fig.
4, B and C, respectively.
Both the N-terminal and C-terminal Regions of mGMRa Are
Essential for Activation of and Association with the I374N
Mutant—To broadly define the regions of the mGMRa extra-
cellular domain required for the constitutive activation of
I374N, two FLAG-tagged extracellular truncation mutants
were generated. One of these, FmaD1, lacked residues Leu15-
Ala96, which comprise the N-terminal domain, whereas the
other, FmaD2, lacked residues Leu15-Glu194, which also in-
cludes domain 1 of the cytokine receptor module (CRM; Fig.
4A). Although these truncation mutants (and full-length
FmGMRa) were efficiently expressed on the surface of G418-
resistant cells (Fig. 4B), neither truncation mutant was able to
confer factor independence on BAF/I374N cells (Fig. 4C), indi-
cating that the N-terminal domain of mGMRa is required for
constitutive activation of I374N. Furthermore, the inability of
BAF/I374N cells expressing the maD1 mutant to proliferate in
the presence of mGM-CSF suggests that the N-terminal do-
main of mGMRa is also important in normal mGMR function.
Considering that the cytoplasmic domain of GMRa is essen-
tial for normal GM-CSF-mediated cell growth (33), we also
investigated whether the cytoplasmic domain of mGMRa was
required for constitutive signaling by I374N. We therefore gen-
erated a cytoplasmic truncation mutant, Fmat3, which lacked
FIG. 5. Analysis of BAF/I374N cells
expressing FmGMRa extracellular
and cytoplasmic truncation mutants.
A, schematic illustration of the truncated
FmGMRa subunits showing the regions
deleted in each truncation mutant. For
comparison, the full-length FmGMRa is
also shown. The asterisks represent the C
terminus of the depicted subunits. B, flow
cytometric analysis of BAF/I374N cells
superinfected with full-length and trun-
cated FmGMRa subunits. Procedures, no-
menclature, and axes are as in Fig. 1A.
Also shown are “parental” BAF/I374N
cells. C, proliferation assay of the BAF/
I374N cells depicted in B in the presence
of mIL-3 (300 units/ml) or mGM-CSF (80
units/ml) or in the absence of either fac-
tor, as indicated.
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the C-terminal 14 amino acids of mGMRa (Fig. 5A). Although
G418-resistant BAF/I374N infectants efficiently expressed
Fmat3 (Fig. 5B), these cells failed to grow in the absence of
factor (Fig. 5C) or in response to mGM-CSF. This implies that
the C-terminal 14 amino acids of mGMRa are essential for
mediating factor-independent growth conferred by I374N and
also for normal mGM-CSF-mediated growth.
We next examined whether the inability of the extracellular
and cytoplasmic truncation mGMRa mutants to confer factor
independence on BAF/I374N cells was due to a failure to asso-
ciate with I374N. Lysates from BAF/I374N cells expressing the
FmaD1 extracellular truncation and the Fmat3 cytoplasmic
truncation were therefore subjected to immunoprecipitation
with an anti-FLAG antibody, followed by immunoblot analysis
with an anti-hbc antibody. As shown in Fig. 6A, the I374N
mutant was precipitated when co-expressed with the full-
length FmGMRa subunit but not with the truncated FmGMRa
subunits. Reprobing with an anti-FLAG antibody demon-
strated that both full-length and truncated FmGMRa subunits
were themselves immunoprecipitated (Fig. 6B), and immuno-
blot analysis of whole cell lysates with an anti-hbc antibody
confirmed that comparable levels of the I374N mutant were
expressed in the cells (Fig. 6C). Thus, these data demonstrate
that both the N-terminal and C-terminal regions of mGMRa
are essential for the association with I374N and, together with
the data presented in Fig. 5, that the constitutive activity of
I374N is dependent upon this association.
Species Specificity of GMRa for the Constitutive Activation of
I374N Lies in Its Extracellular and/or Transmembrane Do-
mains—In view of our previous observations that co-expression
of the human GMRa subunit with I374N in BAF-B03 and
CTLL-2 cells did not lead to factor-independent growth (16, 27),
the ability of the mouse GMRa subunit to facilitate constitutive
activity of I374N in BAF-B03 and CTL-EN cells was somewhat
surprising. To define which region(s) of the GMRa subunit
govern this apparent species specificity, we constructed a series
of chimeric GMRa subunits containing regions from both spe-
cies (Fig. 7A). These chimeras, along with the normal FmGMRa
and hGMRa subunits, were then introduced into BAF/I374N
cells and tested for their ability to confer factor independence.
Flow cytometric analyses confirmed that while the chimeric
GMRa subunits were co-expressed with the I374N mutant (Fig.
7B), only cells co-expressing the Fmaha1 chimera or, as ex-
pected, the normal FmGMRa subunit with the I374N mutant
exhibited factor-independent proliferation (Fig. 7C). Thus, the
species specificity lies in the extracellular and/or transmem-
brane domains of mGMRa. Furthermore, since chimeras con-
taining only the mouse N-terminal domain (Fmaha2) or the
mouse extracellular CRM and transmembrane domain
(hama2) were unable to confer factor independence on BAF-
B03 cells, it is likely that both of the mGMRa regions present
in these chimeras contribute to the species-specific require-
ment for mGMRa for I374N activity.
The I374N Mutant Confers Factor Independence on Human
Hemopoietic Cells: A Possible Role for hGMRa in the Constitu-
tive Activity of I374N in Human Cells—Although the human
GMRa subunit was unable to facilitate the constitutive activity
of I374N in mouse BAF-B03 and CTLL-2 cells (16, 27) (see also
Fig. 7), it was conceivable that the I374N mutant might be
constitutively active in human cells expressing hGMRa. We
therefore introduced this mutant and, as a control, wild-type
hbc into human GM-CSF/IL-3/erythropoietin-dependent UT7
cells and tested these cells for factor-independent proliferation.
To distinguish between the introduced b-subunits and the en-
dogenous b-subunits expressed by UT7 cells, we inserted an
11-amino acid HSV-derived epitope at the N terminus of both
wild-type and I374N b-subunits. Cells infected with these mod-
ified b-subunits were then selected for G418 resistance or
growth in medium without factor. The surface expression of the
introduced subunits was confirmed by flow cytometric analysis
of infected cells stained with both anti-hbc and anti-HSV an-
tibodies (Fig. 8A). In two independent experiments, one of
which is shown in Fig. 8B, the I374N mutant allowed factor-
independent proliferation of UT7 cells. Factor independence
was not the result of low level autocrine growth factor produc-
tion, since conditioned medium from factor-independent cell
pools did not support the growth of uninfected UT7 cells (data
not shown).
Unfortunately, to the best of our knowledge, no human factor-
dependent hemopoietic cell lines “equivalent” to BAF-B03 cells,
i.e. that lack human GMRa, are available; thus, we could not
directly test the requirement for human GMRa by I374N in
human hemopoietic cells. Notably, however, flow cytometric
analysis with an anti-hGMRa antibody revealed that the ex-
pression of hGMRa was significantly up-regulated on the sur-
face of factor-independent cells expressing I374N (FI *I374N
cells) compared with uninfected cells or G418-resistant cells
(expressing wild-type hbc or I374N) that were not selected for
factor independence (Fig. 8C). Importantly, the increase in
hGMRa expression specifically correlated with the factor inde-
pendence of I374N-expressing cells. This increase in hGMRa
expression was not simply a function of high level b-subunit
expression (see FI *I374N histogram in Fig. 8A), since infected
UT7 cells that were sorted for comparably high levels of HSV-
tagged wild-type hbc exhibited a similar low level of hGMRa
expression to the unsorted cells (*wt) shown in Fig. 8C (data
not shown).
DISCUSSION
Constitutive Activation of I374N in Mouse Cells Requires
mGMRa—The I374N mutation in the extracellular domain of
hbc confers factor independence on mouse FDC-P1 cells but not
FIG. 6. Extracellular and cytoplasmic truncations of FmGMRa
abolish the co-immunoprecipitation of FmGMRa and I374N
from BAF-B03 cells. A and B, the BAF-B03 cells expressing the
indicated subunits were incubated in medium without factor and ly-
sates were immunoprecipitated (IP) with the anti-FLAG antibody M2.
Immunoprecipitated proteins were analyzed by immunoblotting (IB)
with the anti-hbc antibody 1C1 (A) or with the anti-FLAG antibody M2
(B). The asterisk by Fma in B indicates that the small C-terminal
deletion mutant Fmat3 ran at the same size as the full-length FmGMRa
under the gel conditions employed. C, whole cell lysates from the
indicated BAF-B03 cells were subjected to immunoblotting with the
anti-hbc antibody 1C1.
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BAF-B03 or CTLL-2 cells (16), raising the possibility that cell
type-specific signaling molecules are involved in its activation.
In this study, we have employed retroviral expression cloning
to identify the mGMRa subunit as one such molecule, since its
introduction into BAF-B03 and CTL-EN (a derivative of
CTLL-2) cells expressing the I374N mutant conferred factor
independence. Importantly, the absence of the mouse GMR and
IL-3R in CTL-EN cells indicates that the mechanism of activa-
tion of I374N does not require any subunits, apart from
mGMRa, of these receptors. In contrast, another hbc mutant,
V449E, that confers factor independence on both FDC-P1 and
BAF-B03 cells (16) is not constitutively active when co-ex-
pressed with mGMRa in CTL-EN cells. This suggests that the
I374N and V449E mutants are activated by fundamentally
different mechanisms.
Physical Association of I374N and mGMRa—Co-immuno-
precipitation experiments demonstrated that one effect of the
I374N mutation in hbc is to induce constitutive association
with mGMRa. The constitutive association between these sub-
units is reminiscent of a recent report in which hGMRa and
FIG. 7. Analysis of BAF/I374N cells infected with retroviruses encoding chimeric mouse and human GMRa subunits. A, schematic
illustration of chimeric GMRa subunits. Regions from the mouse GMRa are shown in white, whereas regions from the human GMRa are shown
in black. For comparison, the normal FmGMRa and hGMRa subunits are also shown. B, flow cytometric analysis of BAF/I374N cells that were
superinfected with retroviruses encoding normal and chimeric GMRa subunits and stained with the anti-FLAG antibody M2 (dotted line), the
anti-hGMRa antibody 8G6 (thick solid line), and the anti-hbc antibody 1C1 (thin solid line). Axes are as in Fig. 1A. C, proliferation assay of the
BAF/I374N cells depicted in B in the presence of mIL-3 (300 units/ml), mGM-CSF (80 units/ml), or hGM-CSF (1 ng/ml) or in the absence of any
factor, as indicated.
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wild-type hbc were co-immunoprecipitated from cell lines in
the absence of GM-CSF (32). Factor-independent association
with hbc appears to be a unique property of GMRa, since
similar preformed complexes could not be detected with hIL-
3Ra or hIL-5Ra (32). This may in part explain the specific
requirement for mGMRa, as opposed to mIL-3Ra, for constitu-
tive activity of I374N.
We observed that deletions in the extracellular N-terminal
domain of mGMRa abolished both the constitutive activity of
I374N and the association between I374N and mGMRa, as well
as mGM-CSF-induced proliferative signaling. While the corre-
sponding domains of the hIL-3Ra and hIL-5Ra subunits have
been reported to play a critical role in ligand binding (34–36),
our demonstration that the N-terminal domain of mGMRa is
required for association with the hbc mutant suggests that this
domain may also play a role in receptor subunit assembly.
Our observation that the cytoplasmic domain of GMRa is
needed for the activity of I374N was not unexpected, since
deletion of the cytoplasmic domains of GMRa, IL-3Ra, and
IL-5Ra renders these receptors inactive in proliferative signal-
ing (33, 34, 37). Normally, however, a-subunit cytoplasmic
truncations do not detectably affect the association of a- and
b-subunits, since truncated a-subunits still form high affinity
ligand-binding receptors (33, 34, 37), and a cytoplasmic trun-
cation of hGMRa could still associate with hbc in the preformed
hGMR complex described by Woodcock et al. (32). Thus, it is
surprising that deletion of the C-terminal 14 amino acids of
mGMRa also abolished the association between mGMRa and
I374N. Nevertheless, this observation suggests that there may
be a degree of interaction between the intracellular domains of
a- and b-subunits and that the effect of such an interaction may
only be detectable in the context of weaker extracellular inter-
actions between mGMRa and I374N as compared with those
between wild-type hbc and hGMRa.
Most importantly, however, the fact that (i) mGMRa associ-
ates with the I374N mutant but not with wild-type hbc and (ii)
association of mGMRa mutants with I374N correlates with
their ability to allow constitutive receptor activity suggests
that induction of this association is essential for hbc activation.
However, constitutive association of hGMRa with hbc per se is
FIG. 8. Analysis of human UT7 cells
infected with the I374N mutant. A,
flow cytometric analysis of G418-resist-
ant UT7 cells infected with retroviruses
encoding the HSV-tagged (as shown by
asterisks) wild-type and I374N b-sub-
units, except for the panel labeled FI
*I374N, which shows staining of cells in-
fected with the HSV-tagged I374N mu-
tant and selected for factor-independent
growth. Also shown are analyses of unin-
fected UT7 cells. Cells were stained with
an irrelevant control antibody (dashed
line), the anti-hbc antibody 1C1 (thin
solid line), and the anti-HSV antibody
(dotted line) by high sensitivity immuno-
fluorescence. The axes are as in Fig. 1A.
B, proliferation assay of the UT7 cells de-
picted in A in the presence and absence of
human GM-CSF (2 ng/ml). C, flow cyto-
metric analysis of hGMRa expression on
the surface of the UT7 cells depicted in A.
Cells were stained with the anti-hGMRa
antibody 8G6 by high sensitivity immu-
nofluorescence. The axes are as in Fig. 1A.
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not sufficient for receptor activation (32); thus, it is likely that
the I374N mutation has additional effects such as mimicking a
ligand-induced conformational change in hbc, as we have sug-
gested previously (27, 38).
Determinants of the Species-specific Requirement for
GMRa for the Constitutive Activity of I374N—In view of the
ability of mouse GMRa to allow constitutive activity of I374N
in mouse cells, it is somewhat surprising that co-expression
of the human GMRa subunit with I374N in mouse BAF-B03
and CTLL-2 cells does not lead to factor-independent prolif-
eration (Refs. 16 and 27; see also Fig. 7C). This is not due to
the inability of I374N to interact with hGMRa because their
co-expression in BAF-B03 and CTLL-2 cells results in the
formation of a high affinity receptor and generation of a
proliferative signal in response to human GM-CSF (16, 27).
Moreover, I374N, like wild-type hbc (32), also efficiently co-
immunoprecipitates with hGMRa in the absence of hGM-CSF
(Fig. 4).
Our studies with mouse/human chimeric GMRa subunits
showed that only the chimera containing the entire extracellu-
lar and transmembrane domains of mGMRa conferred factor
independence on BAF/I374N cells, while in contrast, the hu-
man and mouse cytoplasmic domains were interchangeable.
This suggests two possible explanations for species specificity:
(i) that the extracellular domain of mGMRa interacts with
I374N in a different manner from that of its human homologue,
to allow formation of an active complex in the absence of ligand
or (ii) that mGMRa interacts with a membrane-spanning ac-
cessory signaling molecule in a species-specific manner. The
latter explanation would also suggest that species specificity
might also be a function of the host cell species, i.e. that the
accessory molecule might interact preferentially with the
GMRa subunit of the same species. However, the fact that the
I374N mutant was able to confer factor-independent prolifera-
tion on human GM-CSF/IL-3/erythropoietin-dependent UT7
cells argues against an exclusive requirement for murine
GMRa. Moreover, the expression of hGMRa on the surface of
the factor-independent cells was significantly up-regulated,
suggesting that selection for factor independence also selected
for hGMRa subunit expression. This is consistent with the
notion that GMRa is involved in the constitutive activation of
I374N in these cells also and that the species-specific require-
ment of GMRa for the constitutive activity of I374N may reflect
the species of cell in which the mutant is expressed.
The relevance of the requirement for GMRa by I374N, and
indeed other extracellular hbc mutants, to the activity of these
mutants in primary hemopoietic cells should be noted. Retro-
viral infection of mouse fetal liver progenitors with the I374N
mutant and another extracellular hbc mutant (FID; Ref. 39)
results in the formation of factor-independent cells of only
granulocytic and monocytic lineages (40), the two major lin-
eages controlled by GM-CSF (reviewed in Ref. 1). This obser-
vation is consistent with the notion that the constitutive activ-
ity of I374N and other extracellular hbc mutants is restricted
to cells expressing GMRa.
Finally, the prediction that the extracellular (I374N) and
transmembrane (V449E) constitutive mutants of hbc appear to
act (at least in part) by inducing a-b or b-b dimerization,
respectively, is interesting in light of evidence that the wild-
type GMR/IL3R/IL5R may contain both a-b and b-b dimers
(see the Introduction). It is tempting to speculate that each
class of mutant might activate a subset of the multiple, over-
lapping signaling pathways activated by the wild-type receptor
complex. Thus, they may constitute useful tools for dissecting
receptor signaling.
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